<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03173417</url>
  </required_header>
  <id_info>
    <org_study_id>YMCART201702</org_study_id>
    <nct_id>NCT03173417</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)</brief_title>
  <official_title>Safety and Efficacy Evaluation of IM19 CAR-T Cells On CD19+ Refractory or Relapsed B-ALL Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19
      Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19
      Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia and determine the best
      dosage.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of study related adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>defined as &gt;= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment Adverse events assessed according to NCI-CTCAE v4.0 criteria 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>2 years</time_frame>
    <description>An objective response is defined as: (1) a morphologic complete response (CR) or (2) a complete response with incomplete recovery of counts (CRi) (based on NCCN guidelines (National Comprehensive Cancer Network (NCCN), 2014) or (3) a negative minimal residual disease assessed by flow cytometry</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>IM19 CART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IM19 CAR-T</intervention_name>
    <description>T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor</description>
    <arm_group_label>IM19 CART</arm_group_label>
    <other_name>IM19</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine and cyclophosphamide</intervention_name>
    <description>Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days</description>
    <arm_group_label>IM19 CART</arm_group_label>
    <other_name>FC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with CD19+ Refractory or Relapsed B-ALL（At least 2 prior combination
             chemotherapy regimens）

          2. To be aged 3 to 75 years

          3. Blast in blood ≤ 30%

          4. ECOG score ≤2

          5. Women of childbearing potential must have a urine pregnancy test taken and proven
             negative prior to the treatment. All patients agree to use reliable methods of
             contraception during the trial period and until follow-up for the last time.

          6. Voluntary participation in the clinical trials and sign the informed consent.

        Exclusion Criteria:

          1. Intracranial hypertension or unconsciousness

          2. Respiratory failure

          3. CD19 negative

          4. Disseminated intravascular coagulation

          5. ALT /AST&gt;3 x normal value; Creatinine&gt; 1.5 x normal value; Bilirubin &gt;2.0 x normal
             value

          6. Hematosepsis or Uncontrolled active infection

          7. Uncontrolled diabetes

          8. Abalienation;

          9. WHO Sscore &gt;3

         10. Patients in pregnancy or breast-feeding period

         11. Previously treatment with any gene therapy products

         12. Any uncontrolled medical disorders that the researchers consider are not eligible to
             participate the clinical trial

         13. Any situation that would increase dangerousness of subjects or disturb the outcome of
             the clinical study according to the researcher's evaluation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PEIHUA LU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Yanda Ludaopei Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xin-an Lu, Dr</last_name>
    <phone>86-189-1157-6946</phone>
    <email>luxinan@immunochina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hebei Yanda Ludaopei Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinan lu, Dr</last_name>
      <email>luxinan@immunochina.com</email>
    </contact>
    <contact_backup>
      <phone>86-189-1157-6946</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2017</study_first_submitted>
  <study_first_submitted_qc>May 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>June 1, 2017</last_update_submitted>
  <last_update_submitted_qc>June 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

